{"created":"2024-12-12T10:21:05.020295+00:00","id":2011429,"links":{},"metadata":{"_buckets":{"deposit":"46ba06ba-d749-4f68-82e7-cb146ffbc02e"},"_deposit":{"created_by":7,"id":"2011429","owners":[7],"pid":{"revision_id":0,"type":"depid","value":"2011429"},"status":"published"},"_oai":{"id":"oai:tokushima-u.repo.nii.ac.jp:02011429","sets":["1713853213384:1713853295607"]},"author_link":["1623","573"],"control_number":"2011429","item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2022-10-25","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"101707","bibliographicVolumeNumber":"53","bibliographic_titles":[{"bibliographic_title":"eClinicalMedicine","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease caused by the loss of motor neurons, and development of effective medicines is urgently required. Induced pluripotent stem cell (iPSC)-based drug repurposing identified the Src/c-Abl inhibitor bosutinib, which is approved for the treatment of chronic myelogenous leukemia (CML), as a candidate for the molecular targeted therapy of ALS.\nMethods: An open-label, multicentre, dose-escalation phase 1 study using a 3 + 3 design was conducted in 4 hospitals in Japan to evaluate the safety and tolerability of bosutinib in patients with ALS. Furthermore, the exploratory efficacy was evaluated using Revised ALS Functional Rating Scale (ALSFRS-R), predictive biomarkers including plasma neurofilament light chain (NFL) were explored, and single-cell RNA sequencing of iPSC-derived motor neurons was conducted. Patients, whose total ALSFRS-R scores decreased by 1–3 points during the 12 week, received escalating doses starting from 100 mg quaque die (QD) up to 400 mg QD based on dose-limiting toxicity (DLT) occurrence, and all participants who received one dose of the study drug were included in the primary analysis. This trial is registered with ClinicalTrials.gov, NCT04744532, as Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic Lateral Sclerosis Medicine (iDReAM) study.\nFindings: Between March 29, 2019 and May 7, 2021, 20 patients were enrolled, 13 of whom received bosutinib treatment and 12 were included in the safety and efficacy analyses. No DLTs were observed up to 300 mg QD, but DLTs were observed in 3/3 patients of the 400 mg QD cohort. In all patients receiving 100 mg–400 mg, the prevalent adverse events (AEs) were gastrointestinal AEs in 12 patients (92.3%), liver function related AEs in 7 patients (53.8%), and rash in 3 patients (23.1%). The safety profile was consistent with that known for CML treatment, and ALS-specific AEs were not observed. A subset of patients (5/9 patients) was found to respond well to bosutinib treatment over the 12-week treatment period. It was found that the treatment-responsive patients could be distinguished by their lower levels of plasma NFL. Furthermore, single-cell RNA sequencing of iPSC-derived motor neurons revealed the pathogenesis related molecular signature in patients with ALS showing responsiveness to bosutinib.\nInterpretation: This is the first trial of a Src/c-Abl inhibitor, bosutinib, for patients with ALS. The safety and tolerability of bosutinib up to 300 mg, not 400 mg, in ALS were described, and responsiveness of patients on motor function was observed. Since this was an open-label trial within a short period with a limited number of patients, further clinical trials will be required.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Elsevier","subitem_publisher_language":"en"}]},"item_10001_rights_15":{"attribute_name":"権利情報","attribute_value_mlt":[{"subitem_rights":"This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).","subitem_rights_language":"en"}]},"item_10001_source_id_9":{"attribute_name":"収録物ID","attribute_value_mlt":[{"subitem_source_identifier":"25895370","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_1715043197608":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access"}]},"item_1722929371688":{"attribute_name":"出版社版DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_language":"ja","subitem_relation_name_text":"10.1016/j.eclinm.2022.101707"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1016/j.eclinm.2022.101707","subitem_relation_type_select":"DOI"}}]},"item_1723180141928":{"attribute_name":"EID","attribute_value_mlt":[{"subitem_identifier_type":"URI","subitem_identifier_uri":"396474"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"イマムラ, ケイコ","creatorNameLang":"ja"},{"creatorName":"イマムラ, ケイコ","creatorNameLang":"ja-Kana"},{"creatorName":"Imamura, Keiko","creatorNameLang":"en"}]},{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"http://www.isni.org/isni/"}],"affiliationNames":[{"affiliationNameLang":"ja"}]}],"creatorNames":[{"creatorName":"和泉, 唯信","creatorNameLang":"ja"},{"creatorName":"イズミ, ユイシン","creatorNameLang":"ja-Kana"},{"creatorName":"Izumi, Yuishin","creatorNameLang":"en"}],"familyNames":[{"familyName":"和泉","familyNameLang":"ja"},{"familyName":"イズミ","familyNameLang":"ja-Kana"},{"familyName":"Izumi","familyNameLang":"en"}],"givenNames":[{"givenName":"唯信","givenNameLang":"ja"},{"givenName":"ユイシン","givenNameLang":"ja-Kana"},{"givenName":"Yuishin","givenNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1623","nameIdentifierScheme":"WEKO"},{"nameIdentifier":"60227/profile-ja.html","nameIdentifierScheme":"徳島大学 教育研究者総覧","nameIdentifierURI":"http://pub2.db.tokushima-u.ac.jp/ERD/person/60227/profile-ja.html"},{"nameIdentifier":"10335812","nameIdentifierScheme":"e-Rad_Researcher","nameIdentifierURI":"https://nrid.nii.ac.jp/ja/search/?qm=10335812"}]},{"creatorNames":[{"creatorName":"ナガイ, マキコ","creatorNameLang":"ja"},{"creatorName":"ナガイ, マキコ","creatorNameLang":"ja-Kana"},{"creatorName":"Nagai, Makiko","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"ニシヤマ, カズトシ","creatorNameLang":"ja"},{"creatorName":"ニシヤマ, カズトシ","creatorNameLang":"ja-Kana"},{"creatorName":"Nishiyama, Kazutoshi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"ワタナベ, ヤスヒロ","creatorNameLang":"ja"},{"creatorName":"ワタナベ, ヤスヒロ","creatorNameLang":"ja-Kana"},{"creatorName":"Watanabe, Yasuhiro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"ハナジマ, リツコ","creatorNameLang":"ja"},{"creatorName":"ハナジマ, リツコ","creatorNameLang":"ja-Kana"},{"creatorName":"Hanajima, Ritsuko","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"エガワ, ナオヒロ","creatorNameLang":"ja"},{"creatorName":"エガワ, ナオヒロ","creatorNameLang":"ja-Kana"},{"creatorName":"Egawa, Naohiro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"アヤキ, タカシ","creatorNameLang":"ja"},{"creatorName":"アヤキ, タカシ","creatorNameLang":"ja-Kana"},{"creatorName":"Ayaki, Takashi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"オキ, リョウスケ","creatorNameLang":"ja"},{"creatorName":"オキ, リョウスケ","creatorNameLang":"ja-Kana"},{"creatorName":"Oki, Ryosuke","creatorNameLang":"en"}]},{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"http://www.isni.org/isni/"}],"affiliationNames":[{"affiliationNameLang":"ja"}]}],"creatorNames":[{"creatorName":"藤田, 浩司","creatorNameLang":"ja"},{"creatorName":"フジタ, コウジ","creatorNameLang":"ja-Kana"},{"creatorName":"Fujita, Kouji","creatorNameLang":"en"}],"familyNames":[{"familyName":"藤田","familyNameLang":"ja"},{"familyName":"フジタ","familyNameLang":"ja-Kana"},{"familyName":"Fujita","familyNameLang":"en"}],"givenNames":[{"givenName":"浩司","givenNameLang":"ja"},{"givenName":"コウジ","givenNameLang":"ja-Kana"},{"givenName":"Kouji","givenNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"573","nameIdentifierScheme":"WEKO"},{"nameIdentifier":"246775/profile-ja.html","nameIdentifierScheme":"徳島大学 教育研究者総覧","nameIdentifierURI":"http://pub2.db.tokushima-u.ac.jp/ERD/person/246775/profile-ja.html"},{"nameIdentifier":"80601765","nameIdentifierScheme":"e-Rad_Researcher","nameIdentifierURI":"https://nrid.nii.ac.jp/ja/search/?qm=80601765"}]},{"creatorNames":[{"creatorName":"ウオズミ, リュウジ","creatorNameLang":"ja"},{"creatorName":"ウオズミ, リュウジ","creatorNameLang":"ja-Kana"},{"creatorName":"Uozumi, Ryuji","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"モリナガ, アキコ","creatorNameLang":"ja"},{"creatorName":"モリナガ, アキコ","creatorNameLang":"ja-Kana"},{"creatorName":"Morinaga, Akiko","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"ヒロハシ, トモコ","creatorNameLang":"ja"},{"creatorName":"ヒロハシ, トモコ","creatorNameLang":"ja-Kana"},{"creatorName":"Hirohashi, Tomoko","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"フジイ, ヨウスケ","creatorNameLang":"ja"},{"creatorName":"フジイ, ヨウスケ","creatorNameLang":"ja-Kana"},{"creatorName":"Fujii, Yosuke","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"ヤマモト, タクヤ","creatorNameLang":"ja"},{"creatorName":"ヤマモト, タクヤ","creatorNameLang":"ja-Kana"},{"creatorName":"Yamamoto, Takuya","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"タテベ, ハルツグ","creatorNameLang":"ja"},{"creatorName":"タテベ, ハルツグ","creatorNameLang":"ja-Kana"},{"creatorName":"Tatebe, Harutsugu","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"トクダ, タカヒコ","creatorNameLang":"ja"},{"creatorName":"トクダ, タカヒコ","creatorNameLang":"ja-Kana"},{"creatorName":"Tokuda, Takahiko","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"タカハシ, ナオト","creatorNameLang":"ja"},{"creatorName":"タカハシ, ナオト","creatorNameLang":"ja-Kana"},{"creatorName":"Takahashi, Naoto","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"モリタ, サトシ","creatorNameLang":"ja"},{"creatorName":"モリタ, サトシ","creatorNameLang":"ja-Kana"},{"creatorName":"Morita, Satoshi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"タカハシ, リョウスケ","creatorNameLang":"ja"},{"creatorName":"タカハシ, リョウスケ","creatorNameLang":"ja-Kana"},{"creatorName":"Takahashi, Ryosuke","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"イノウエ, ハルヒサ","creatorNameLang":"ja"},{"creatorName":"イノウエ, ハルヒサ","creatorNameLang":"ja-Kana"},{"creatorName":"Inoue, Haruhisa","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2024-01-15"}],"displaytype":"detail","filename":"eClinicalM_53_101707.pdf","filesize":[{"value":"958 KB"}],"format":"application/pdf","licensetype":"license_5","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://tokushima-u.repo.nii.ac.jp/record/2011429/files/eClinicalM_53_101707.pdf"},"version_id":"9050ac3a-68b3-4b6d-ab3a-5b3758c356b2"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study) : A multicentre, open-label, dose-escalation phase 1 trial","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study) : A multicentre, open-label, dose-escalation phase 1 trial","subitem_title_language":"en"}]},"item_type_id":"40001","owner":"7","path":["1713853295607"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2024-01-15"},"publish_date":"2024-01-15","publish_status":"0","recid":"2011429","relation_version_is_last":true,"title":["Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study) : A multicentre, open-label, dose-escalation phase 1 trial"],"weko_creator_id":"7","weko_shared_id":-1},"updated":"2025-01-30T01:55:52.887929+00:00"}